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Background/Aims: While chemoradiotherapy (CRT) is con-
sidered to be a reasonable treatment for locally advanced 
pancreatic cancer (LAPC), there is little information about 
the associated risk of gastrointestinal (GI) hemorrhage. We 
investigated the clinical features of GI toxicity after CRT in 
patients with LAPC and examined the effect of GI hemor-
rhage on survival. Methods: Patients enrolled in this study 
had received CRT for pathologically proven LAPC. Their medi-
cal records were retrospectively reviewed. Results: A total of 
156 patients with LAPC (median age, 65 years; range, 39 to 
90 years) who received treatment between August 2005 and 
March 2009 were included in this study. The most common 
GI toxicities were ulcer formation (25.6%) and hemorrhage 
(25.6%), and the most common grade 3 to grade 5 GI toxic-
ity was hemorrhage (65%). The origins of GI hemorrhage 
were gastric ulcer (37.5%), duodenal ulcer (37.5%), and ra-
diation gastritis (15.0%). The independent risk factor for GI 
hemorrhage was tumor location in the pancreatic body. The 
median overall survival of the patients with a GI hemorrhage 
was 13.8 months (range, 2.8 to 50.8 months) and was not 
significantly different from that of patients without GI hemor-
rhage. Conclusions: GI hemorrhage was common in patients 
with LAPC after CRT. Although GI hemorrhage was controlled 
with endoscopic hemostasis, preventive measures should 
be investigated to reduce needless suffering. (Gut Liver 
2013;7:106-111)
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INTRODUCTION
Pancreatic cancer is the fourth leading cause of cancer-related 
deaths in the United States.1 Surgical resection is the only cura-
tive treatment for pancreatic cancer.2 However, only 5% to 25% 
of patients with pancreatic cancer are candidates for curative 
pancreatectomy.
Locally advanced pancreatic cancer (LAPC) is surgically un-
resectable nonmetastatic disease, which includes the cases of 
extensive peripancreatic lymph node involvement and major 
vasculatures involvement.3 The median survival time for pa-
tients with LAPC is only 9 to 10 months.4
Chemoradiotherapy (CRT) is a reasonable treatment modality 
for LAPC because it is known to increase survival in patients 
with LAPC.5-7 CRT has been frequently used instead of chemo-
therapy alone or radiotherapy alone. However, overall toxic 
effects of CRT are greater than those of chemotherapy alone.8 
Such adverse effects of CRT limit the maximum dose of chemo-
therapy and radiotherapy, and lead to unfavorable treatment 
results.9
CRT for treatment of LAPC produces unique gastrointestinal 
(GI) toxicities, including ulcer and hemorrhage in the stomach 
and duodenum that are included in the radiation field. However, 
to our knowledge, there are a few data focusing on GI hemor-
rhage of CRT for treatment of LAPC. In addition, the effect of 
GI hemorrhage on survival of patients with LAPC has not been 
evaluated. GI hemorrhage of CRT needs to be examined to 
prevent adverse events and to develop methods to reduce the 
severity of such events. Indeed, in clinical practice, we experi-
enced many patients with CRT-induced GI hemorrhage, which 
led us to perform this study. Thus, we examined clinical features 
of GI hemorrhage of CRT in patients with LAPC, and the effect 
of GI hemorrhage on survival.
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MATERIALS AND METHODS
1. Patients
Patients who received concurrent CRT for treatment of LAPC 
at Severance Hospital in Seoul, Korea, between August 2005 
and March 2009 were selected for this study. Inclusion criteria 
included pathologically-proven pancreatic adenocarcinoma, age 
of over 20 years, and the Eastern Cooperative Oncology Group 
performance status of 0 to 2. Exclusion criteria included patients 
who had received chemotherapy or surgery before CRT, and pa-
tients with scheduled radiotherapy less than 4,000 cGy. Patients 
who had not completed their scheduled radiation therapy were 
also excluded for per protocol analysis.
2. Treatment for LAPC
For regression analysis, regimens of chemotherapy and radio-
therapy were classified into several groups. All chemotherapy 
regimens of CRT performed for LAPC were classified into three 
groups: gemcitabine, 5-fluorouracil (5-FU), and 5-FU plus gem-
citabine. Gemcitabine group was given 1,000 mg/m2 of gem-
citabine on days 1, 8, and 15 of a 4-week regimen or gemcitabi-
ne (same as above) along with 70 mg/m2 of cisplatin on day 1 
of the regimen. 5-FU group received either 5-FU (1,000 mg/m2 
on days 1 to 3 of a 4-week regimen) or; TS-1 (60 to 80 mg for 
2 weeks); or a combination of 5-FU (1,000 mg/m2 on days 1 to 
3), etoposide (100 mg/m2 on days 1 to 3), and cisplatin (70 mg/
m2 on day 1). For 5-FU plus gemcitabine group, 1,000 mg/m2 of 
5-FU was given on days 1 to 3, and 1,000 mg/m2 gemcitabine 
on days 1, 8, and 15 of a 4-week regimen.
All radiotherapy regimens of CRT performed for LAPC were 
either three-dimensional (3D) conformal radiotherapy (total 
dose, 4,000 to 5,400 cGy; one dose, 180 to 250 cGy; fraction, 
28) or intensity modulated radiotherapy (total dose, 4,200 to 
6,000 cGy; one dose, 200 to 293 cGy; fraction, 25).
3. GI toxicities
GI toxicities were classified according to the National Cancer 
Institute Common Terminology Criteria for Adverse Events ver-
sion 4.0. In our study, radiation-induced injuries observed with 
endoscopy were defined as telangiectasia, diffuse erythema of 
mucosa, ulcers, and scar formation.10,11
4. Statistical analysis
To investigate the risk factors of GI toxicities by CRT, Pear-
son’s chi-square test for univariate analysis and logistic regres-
sion for multivariate analysis were used. To evaluate survival 
effect of GI hemorrhage, Cox regression test was used. The 
Kaplan-Meier method and the log-rank test were used to com-
pare survival between patients with GI hemorrhage and patients 
without GI hemorrhage.
All analyses were performed using statistical software SPSS 
version 11 (SPSS Inc., Chicago, IL, USA). A p-values lower than 
0.05 indicated significance.
RESULTS
1. Patient characteristics
One hundred fifty-six patients with LAPC were eligible for 
analysis (Table 1). The median age at the time of the diagnosis 
of pancreatic cancer was 65 years, ranging from 35 to 90 years. 
Male patients accounted for 61.5% of the population. The tu-
mors were mostly located at the pancreatic head (63.5%). The 
median size of the tumor was 2.9 cm, ranging from 1.1 to 7.0 
cm. The median level of CA 19-9 was 384 U/mL (range, 0.1 to 
20,000 U/mL). The 3D conformal radiotherapy was delivered to 
119 patients (76.3%), and the median delivered dose was 5,040 
cGy (range, 4,000 to 5,400 cGy). Intensity modulated radio-
therapy was delivered to 37 patients (23.7%), and the median 
delivered dose was 5,842 cGy (range, 4,200 to 6,000 cGy). The 
median follow-up period was 13.2 months (range, 2 to 52.2 
months).
Table 1. Baseline Patient Characteristics
Characteristic Value
Total 156
Age, yr 65 (39-90)
Sex, male:female 96 (61.5):60 (38.5)
Location of tumor
  Head 99 (63.5)
  Body 44 (28.2)
  Tail 13 (8.3)
Size of tumor, cm 3.0 (1.1-7.0)
CA 19-9 at diagnosis, U/mL 384 (0.1-20,000)
Chemotherapy
  5-FU group 48 (30.8)
  Gemcitabine group 93 (59.6)
  5-FU plus gemcitabine group 15 (9.6)
Radiotherapy
  3D conformal radiotherapy
    No. 119 (76.3)
    Radiation dose, cGy 5,040 (4,000-5,400)
  Intensity modulated radiotherapy 
    No. 37 (23.7)
    Radiation dose, cGy 5,842 (4,200-6,000)
Time to GI toxicities, mo 5.2 (0.8-50.8)
  Acute (≤3) 13 (24.5)
  Late (>3) 40 (75.5)
Follow-up periods after CRT, mo 13.2 (2-52.2)
Data are presented as median (range) or number (%).
5-FU, 5-fluorouracil; GI, gastrointestinal; 3D, three-dimensional; CRT, 
chemoradiotherapy.
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2. GI toxicities
The prevalence of GI toxicities was 57.7% (Table 2). There 
were 30 patients with grade 1 or 2 abdominal pain or dyspep-
sia. Two patients had grade 3 anorexia. Nausea and vomiting 
developed in four patients, and these were well controlled with 
appropriate medications. Forty patients (25.6%) had GI hem-
orrhage: nine patients with hematemesis (22.5%), 21 patients 
with melena (52.5%), and 10 patients with hematochezia (25%). 
Eighteen patients (11.5%) had grade 3 or 4 GI hemorrhage, and 
eight patients (5.1%) had grade 5 (death) hemorrhage.
Seventy-eight patients (50%) underwent upper GI endoscopy 
after CRT. There were mucositis in 27.2% of patients, ulcer 
in 45%, and GI hemorrhage with above grade 3 toxicity in 
65%. The median time of development of GI toxicities was 5.2 
months.
3. GI hemorrhage 
Forty patients (25.6%) suffered from GI hemorrhage after CRT 
(Table 3). The median initial hemoglobin was 10.1 g/dL (range, 
7.1 to 15.3 g/dL), which decreased to 7.1 g/dL (range, 3.5 to 
10.8 g/dL) when bleeding. Thirty-five patients underwent upper 
GI endoscopy. The results showed the cause of bleeding to be a 
gastric ulcer in 15 patients (37.5%), duodenal ulcer in 15 (37.5%), 
and radiation gastritis in five (15%). Upper GI endoscopy was 
not performed in five patients upon their guardians’ rejection. 
As the patients were in terminal stages, the guardians did not 
want them to undergo any more examinations. The remaining 
35 patients received endoscopic treatment. Hemorrhage was 
successfully stopped by endoscopic treatment in 31 patients 
(77.5%). The methods of endoscopic hemostasis were hypertonic 
saline-epinephrine injection, human plasmin thrombin injec-
tion, argon plasma coagulation, or hemoclipping. Embolization 
Table 2. Gastrointestinal Toxicities after Chemoradiotherapy According to the National Cancer Institute Common Terminology Criteria Version 4.0
Variable Total G3-G5 G1 G2 G3 G4 G5
Abdominal pain or dyspepsia 30 (19.2) 0 16 14 0 0 0
Anorexia 5 (3.2) 2 (40) 2 1 2 0 0
Nausea 3 (1.9) 0 0 3 0 0 0
Vomiting 1 (0.6) 0 0 1 0 0 0
Mucositis 22 (14.1) 6 (27.2) 15 1 6 0 0
  Stomach 17 (10.8) 5 (29.4) 11 1 5 0 0
  Duodenum 5 (3.2) 1 (20) 4 0 1 0 0
Ulcer 40 (25.6) 18 (45) 11 11 14 1 3
  Stomach 22 (14.1) 7 (31.8) 7 8 7 0 0
  Duodenum 18 (11.5) 11 (61.1) 4 3 7 1 3
Other
  GI hemorrhage 40 (25.6) 26 (65) 0 14 17 1 8
    Stomach 20 (12.8) 9 (45) 0 11 9 0 0
    Duodenum 15 (9.6) 12 (80) 0 3 8 1 3
    Not confirmed* 5 (3.2) 5 (100) 0 0 0 0 5
Data are presented as number (%).
GI, gastrointestinal.
*Endoscopy was not performed, and the focus of bleeding was not confirmed. 
Table 3. Gastrointestinal Hemorrhage after CRT (n=40)
Variable Value
Hemoglobin, g/dL
  Initial 10.1 (7.1-15.3)
  At bleeding 7.1 (3.5-10.8)
Origin 
  Gastric ulcer 15 (37.5)
  Duodenal ulcer 15 (37.5)
  Radiation gastritis 5 (15.0)
  Not confirmed* 5 (15.0)
Severity
  Mild (G1) 0
  Moderate (G2, G3) 31 (77.5)
  Severe (G4, G5) 9 (22.5)
Treatment
  Endoscopic hemostasis 35 (87.5)
  Angiography and embolization 1 (2.5)
  Conservative care 5 (12.5)
Time to GI hemorrhage from CRT, mo 5.4 (0.8-50.8)
Survival time from CRT, mo 13.8 (2.8-50.8)
Data are presented as median (range) or number (%).
CRT, chemoradiotherapy; GI, gastrointestinal.
*Endoscopy was not performed, and the focus of bleeding was not 
confirmed.
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was performed in one of the four other patients, and hemor-
rhage was finally stopped. However, three others died due to GI 
hemorrhage. The mortality of GI hemorrhage was eight patients 
in total (Fig. 1).
The median time from CRT to GI hemorrhage was 5.4 months 
(range, 0.8 to 50.8 months), and the median overall survival was 
Fig. 2. Comparison of survival between gastrointestinal (GI) hemor-
rhage patients and non-GI hemorrhage patients. The overall median 
survival time was 13.1 months in the non-GI hemorrhage group and 
13.5 months in the GI hemorrhage group.
Fig. 1. Treatment flow chart. Treatment of gastrointestinal hemor-
rhage after chemoradiotherapy.
Table 4. Risk Factors for GI Hemorrhage in All Patients (n=156)
Variable
GI hemorrhage GI hemorrhage
Presence (%) p-value* OR 95% CI p-value†
Age, yr 0.144
  ≤65 25 (30.5) 1
  >65 15 (20.3) 0.61 0.27-1.49 0.304
Sex 0.602
  Female 14 (23.3) 1
  Male 26 (27.1) 1.56 0.67-3.64 0.304
Location of tumor 0.007
  Head 19 (19.2) 1
  Body 19 (43.2) 2.99 1.27-7.03 0.033
  Tail 2 (15.4) 0.42 0.08-2.26 0.314
Size of tumor, cm 0.042
  ≤3 16 (19.0) 1
  >3 24 (33.3) 1.94 0.87-4.31 0.102
Chemotherapy 0.311
  5-FU group 10 (20.4) 1
  Gemcitabine group 24 (26.1) 1.58 0.64-3.88 0.319
  5-FU plus gemcitabine group 6 (40.0) 2.70 0.65-11.17 0.168
Radiation modality 0.834
  3D conformal radiotherapy 31 (26.1) 1
  Intensity modulated radiotherapy 9 (24.3) 0.97 0.38-2.42 0.945
CA 19-9, U/mL  0.554
  ≤1,200 27 (24.3) 1
  >1,200 13 (28.9) 1.27 0.54-2.97 0.322
GI, gastrointestinal; OR, odds ratio; CI, confidence interval; 5-FU, 5-fluorouracil; 3D, three-dimensional.
*Chi-square test was used; †Logistic regression was used.
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13.8 months (range, 2.8 to 50.8 months).
4. Risk factors for GI hemorrhage
The association between clinical parameters and the risk of 
GI hemorrhage were analyzed (Table 4). In univariate analysis, 
location of tumor (p=0.007) and size of tumor (p=0.042) were 
risk factors for GI hemorrhage. In multivariate analysis, only 
tumors located on the pancreatic body (odds ratio [OR], 2.99; 
95% confidence interval [CI], 1.27 to 7.03) was a significant risk 
factor for GI hemorrhage. The hazard ratio (HR) was 1.28 (95% 
CI, 0.78 to 2.07) for the effect of GI hemorrhage on survival, 
but it was not significant (Table 5). Male patients had signifi-
cantly higher HR than females (HR, 1.62; 95% CI, 1.07 to 2.43; 
p=0.020). However, there were no difference in the number of 
patients with hypertension or diabetes mellitus between males 
and females (OR, 1.26; 95% CI, 0.66 to 2.40; p=0.492).
5. Survival
At the time of final analysis, 117 patients (75%) were dead. 
The median overall survival after the start of CRT was 13.1 
months (range, 11.3 to 14.9 months). The median overall sur-
vival was 13.1 months (range, 9.9 to 16.3 months) in patients 
without GI hemorrhage and 13.8 months (range, 2.8 to 50.8 
months) in patients with GI hemorrhage (Fig. 2). Although over-
all survival was longer in patients with GI hemorrhage, this dif-
ference was not significant.
DISCUSSION
Our analysis showed that the prevalence of CRT-induced GI 
hemorrhage is frequent and serious if not treated properly. The 
body of the pancreas was the risk factor of GI hemorrhage after 
CRT. The median overall survival was similar with other stud-
ies.5,8,12 This study also showed that GI hemorrhage after CRT 
did not reduce survival of patients with LAPC.
CRT was first introduced in the Gastrointestinal Tumor Study 
Group trial.13 Many studies reported the benefit of CRT, and CRT 
became one of the treatment options for pancreatic cancer.6,7 
Based on the results of several studies, the RT dose of 50 to 60 
Gy (182 cGy/day) is generally used.14,15 A study reported that the 
toxicity was higher in the LAPC group where the radiation dose 
increased up to 55 Gy than in the LAPC group with the dose 
up to 50 Gy; however, patient compliance was similar between 
the groups, and the treatment performance in the former was 
better than that in the latter.16 In studies comparing CRT and 
chemotherapy, however, more cases of toxicity were found in 
the CRT group; thus, care must be taken with regard to the use 
of CRT.17,18
Due to low awareness of GI hemorrhage, the frequency of en-
doscopic examination was quite low. Of 156 patients, 20 were 
examined with endoscopy before CRT and 78 after CRT. Very 
few patients who had GI hemorrhage underwent endoscopic 
study before the onset of bleeding. Had endoscopy also been 
performed in other patients, the chances of finding complica-
tions such as radiation gastritis would have been higher.
The location of the tumor was related with GI hemorrhage. 
As the body of the pancreas is located close to both the stomach 
and duodenum, radiation on the pancreas affects the two organs 
as well. There is no consensus over the best time to perform en-
doscopy after radiotherapy. After CRT, however, GI toxicites are 
likely to develop at anytime. Therefore, it is recommended that 
endoscopy be performed as was done in this study. If abnormal 
findings are found in endoscopy before CRT, preemptive treat-
ment is necessary. Moreover, endoscopy as a baseline study is 
recommended for the comparison with post-CRT endoscopic 
results. Usually CRT is followed by chemotherapy or surgery 
about one month later. Endoscopy is recommended before such 
therapies as GI ulcer or hemorrhage can occur even within 90 
days after CRT. As ulcerative bleeding is highly responsive to 
proton pump inhibitor, its early detection and treatment may 
prevent adverse events. Although the best frequency of endos-
copy may be debatable, yearly or more frequent endoscopy, 
particularly in patients with a history of GI hemorrhage, is 
recommended considering the possibility of delayed ulcer and 
hemorrhage.
This study has several limitations. First, the results were ob-
tained by retrospectively reviewing the medical charts. Second, 
regarding CRT, the chemotherapy-induced adverse effects could 
not be excluded. In this study, a greater number of patients 
received gemcitabine treatment than those who received 5-FU. 
Several studies reported that gemcitabine was more toxic than 
5-FU.19,20 In addition, it was difficult to identify the cause of GI 
hemorrhage after surgery as well as after beginning a chemo-
therapy only regimen following CRT. Third, the low number of 
Table 5. Cox Regression Analysis of the Effect of GI Hemorrhage on 
Survival
Variable HR 95% CI p-value
Age (>65 yr) 1.04 0.70-1.52 0.862
Sex (male) 1.62 1.07-2.43 0.020
Location of tumor
  Body 1.53 0.97-2.39 0.066
  Tail 1.12 0.54-2.28 0.759
Size of tumor (>3 cm) 1.10 0.73-1.65 0.632
Chemotherapy
  Gemcitabine group 0.96 0.62-1.46 0.836
  5-FU plus gemcitabine group 1.60 0.78-3.25 0.197
Radiation modality (3D conformal) 0.92 0.57-1.45 0.708
CA 19-9 (>1,200 U/mL) 1.31 0.87-1.97 0.192
GI hemorrhage (presence) 1.28 0.78-2.07 0.329
GI, gastrointestinal; HR, hazard ratio; CI, confidence interval; 5-FU, 
5-fluorouracil.
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patients who received endoscopy before CRT made it impossible 
to determine if patients developed an ulcer before CRT. Fourth, 
patients who received 3D conformal radiotherapy and inten-
sity modulated radiotherapy were analyzed together, and 37 of 
them received intensity-modulated radiotherapy. To the best 
of our knowledge, there has been no study that compared 3D 
conformal radiotherapy and intensity-modulated radiotherapy. 
Thus, a study is required to investigate if there is any difference 
between the two modalities.
In conclusion, the present results show that GI hemorrhage is 
common in LAPC after CRT. Although the median survival was 
similar regardless of GI hemorrhage, the clinicians need to con-
sider the GI hemorrhage of CRT in LAPC. Extensive studies are 
required to compare the benefits and risks in terms of survival 
and complications between CRT and chemotherapy. In addition, 
studies are required to identify tests or treatments that can re-
duce CRT-induced GI hemorrahge.
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